50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Chronic Myeloid Leukemia

Monday, December 8, 2008: 7:00 AM-9:00 AM

2001-2003-2014-2016 - West (Moscone Center)

Moderators:

Ravi Bhatia and Danilo Perrotti, MD, PhD

7:00 AM

Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34⁺/CD38^- Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL–independent Signals

Paolo Neviani, PhD¹, Ramasamy Santhanam, Ph.D¹^*, Yihui Ma, B.S.²^*, Guido Marcucci, MD³, John C. Byrd, MD⁴, Ching-Shih Chen, Ph.D⁵^*, Jorge Cortes, MD⁶, Michael A. Caligiuri, MD⁴, Claudia Huettner, PhD⁷^*, Ravi Bhatia, MD⁸, Denis-Claude Roy, MD⁹ and Danilo Perrotti, MD, PhD¹

¹Comprehensive Cancer Center, The Ohio State University, Columbus, OH
²Pharmacy, The Ohio State University, Columbus, OH
³Dept. of Hematology/ Oncology, The Ohio State Univ. Med. Ctr., Columbus, OH
⁴The Ohio State University, Columbus, OH
⁵College of Pharmacy, Ohio State University, Columbus, OH
⁶M.D. Anderson Cancer Center, Houston, TX
⁷Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI
⁸Hem/HCT, City of Hope National Medical Center, Duarte, CA
⁹Hematology-Oncology, Hopital Maisonneuve-Rosemont, Montreal, QC, Canada

7:15 AM

190

Suppression of CML Progenitor but Not CML Stem Cell Growth Requires Dual Inhibition of BCR-ABL and KIT

Amie S. Corbin¹^*, Thomas O'Hare¹^*, Brian J. Druker¹ and Michael W.N. Deininger²

¹Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute, Portland, OR
²Hematology and Medical Oncology, Oregon Health & Science University Cancer Institute, Portland, OR

7:30 AM

191

Leukemic Stem Cells and Progenitors Demonstrate Impaired Interaction with the Hematopoietic Microenvironment in Vivo in An Inducible Murine Model of Chronic Myelogenous Leukemia

Amitava Sengupta, PhD¹^* and Jose Cancelas, MD, PhD²

¹Experimental Hematology, CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, Cincinnati, OH
²Hoxworth Blood Center, Univ. of Cincinnati, Cincinnati, OH

7:45 AM

192

Mechanisms Generating free Radicals in CML Stem/Progenitor Cell Populations Causing DNA Damage and Genomic Instability

Margaret Nieborowska-Skorska, MD, PhD¹^*, Mateusz Koptyra, PhD¹^*, Grazyna Hoser, PhD²^*, Regina Ray¹^*, Danielle Ngaba¹^*, Elisabeth Bolton¹^* and Tomasz Skorski, MD, PhD¹

¹Microbiology and Immunology, Temple University, School of Medicine, Philadelphia, PA
²Clinical Cytology, Medical Center for Postgraduate Education, Warsaw, Poland

8:00 AM

193

Differentially Expressed and Novel Transcripts in Highly Purified Chronic Phase CML Stem Cells

Yun Zhao¹^*, Allen Delaney²^*, Afshin Raouf¹^*, Kamini Raghuram¹^*, Haiyan I Li²^*, Angelique Schnerch²^*, Xiaoyan Jiang, MD, PhD¹, Allen C Eaves¹^*, Marco A Marra, PhD² and Connie J. Eaves, PhD¹

¹Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
²Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada

8:15 AM

194

Persistence of Leukemia Stem Cells in Chronic Myelogenous Leukemia Patients in Complete Cytogenetic Remission on Imatinib Treatment for 5 Years

Su Chu, MD^*, Allen Lin^*, Tinisha McDonald^*, David S. Snyder, MD, Stephen J. Forman, MD and Ravi Bhatia, MD

Division of Hematology and HCT, City of Hope National Medical Center, Duarte, CA

8:30 AM

195

Selective Anti-Leukemia Targeting of the Interaction Between BCR/ABL and Mammalian RecA Homologs

Artur Slupianek, PhD, Shuyue Ren, MD, PhD and Tomasz Skorski, MD, PhD

Microbiology and Immunology, Temple University, Philadelphia, PA

8:45 AM

196

Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients

Jane R Engler^*, Amity Frede^*, Andrew C W Zannettino, PhD^*, Deborah L White, PhD^* and Timothy P Hughes, MD

Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

631.O2.8 Chronic Myeloid Leukemia - Stem Cell Biology and Eradication